Stock TRDA ENTRADA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Entrada Therapeutics, Inc.

Equities

TRDA

US29384C1080

Real-time Estimate Cboe BZX
Other stock markets
 14:53:55 14/05/2024 BST 		5-day change 1st Jan Change
14.42 USD +2.67% Intraday chart for Entrada Therapeutics, Inc. +4.39% -3.98%
05-07 Entrada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-13 Entrada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Entrada Therapeutics : Corporate Presentation
PU
Entrada Therapeutics Reports First Quarter 2024 Financial Results
GL
Entrada Therapeutics : Corporate Presentation
PU
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
GL
Entrada Therapeutics : Corporate Presentation
PU
Entrada Therapeutics to Present at Upcoming Investor Conferences
GL
Entrada Therapeutics Promotes Nathan J. Dowden to President
GL
Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDA
PR
Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDA
PR
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
GL
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
AQ
Entrada Therapeutics Reports Third Quarter 2023 Financial Results
GL
Entrada Therapeutics to Present at Upcoming Investor Conferences
GL
Entrada Therapeutics to Present at Upcoming Investor Conferences
AQ
Entrada Therapeutics : Corporate Presentation
PU
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
GL
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
AQ
Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community
GL
Entrada Therapeutics : Corporate Presentation
PU
Entrada Therapeutics to Present at Upcoming Investor Conferences
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TRDA Stock
  4. News Entrada Therapeutics, Inc.
  5. Press Releases